<DOC>
	<DOCNO>NCT00605332</DOCNO>
	<brief_summary>This open label , non-randomized , prospective , multicenter study .</brief_summary>
	<brief_title>Crux Biomedical IVC Filter - Evaluation Crux Inferior Vena Cava Filter System ( Retrieve )</brief_title>
	<detailed_description />
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<criteria>Patients study must meet follow inclusion criterion eligible enrollment : 1 . The patient &gt; 18 year age . 2 . Patient consider candidate IVCF one follow indication : Proven PE Recurrent PE despite adequate anticoagulation Contraindication anticoagulation Inability achieve/maintain therapeutic anticoagulation Iliocaval DVT Large , freefloating proximal ( i.e . ileofemoral ) DVT Massive PE treat thrombolysis/thrombectomy Chronic PE treat thrombectomy Protection thrombolysis iliocaval DVT PE limit cardiopulmonary reserve Poor compliance anticoagulant medication High risk injury worsen anticoagulation ( e.g. , ataxia , fall ) Multitrauma patient high risk PE Surgical patient high risk PE Medical condition high risk PE 3 . Patient vena cava diameter 1728mm . 4 . The patient legal guardian inform nature study agree provision provide informed write consent . 5 . The patient willing available appropriate followup duration study . 6 . The patient suitable IVC anatomy would allow infrarenal placement filter . Patients ANY follow exclusion criterion NOT eligible study : 1 . The patient one follow condition : Renal vein thrombosis IVC thrombosis extend renal vein Duplicate IVC Gonadal vein thrombosis Requires suprarenal filter placement 2 . The patient uncontrolled infectious disease . 3 . The patient risk aseptic PE . 4 . Patient uncontrollable coagulopathy . 5 . Patient exist IVCF . 6 . The patient life expectancy le 6 month . 7 . The patient pregnant . 8 . The patient condition inhibits radiographic visualization IVC . 9 . The patient know allergy intolerance polytetrafluoroethylene ( PTFE ) Nitinol . 10 . The patient know hypersensitivity contrast pretreated . 11 . The patient 's access vessel preclude safe insertion delivery system . 12 . The patient participate another device drug study . Patient must complete follow phase previous study least 30 day prior enrollment trial . The patient may enrol study . 13 . The patient unable and/or unwilling cooperate study procedure require followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>